Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.
From October, 1993 to August, 1994, a post-marketing surveillance study enrolled 9,568 adults and children treated for respiratory tract infections with cefixime in a daily dose of 400 mg or 8 mg/kg body weight, respectively. Twice daily dosage was preferred with adults (60.4%) and children (54.4%). Bronchitis (45.5%) and otitis media (48.0%) were the most frequent indications given for cefixime use in adults and children, respectively. Bacterial analysis was done in 5.4% of adults and in 6.5% of children. With a median therapy of 6 days, cure or improvement was reported in 98.7% of adult patients and in 98.0% of children. Symptoms rapidly improved in a majority of patients. Adverse events occurred in 1.12% of adult patients and 1.92% of children. In 96.7% of all cases the dry syrup was very well or well accepted by children. In conclusion, high efficacy and low incidence of side effects make cefixime a drug of choice for treatment of respiratory tract infections.
Klinge Pharma GmbH, Abteilung Biometrie, München, Germany.
T
T
Hausen
G
G
Weidlich
J
J
Schmitt
D000328:Adult; D020682:Cefixime; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D020682:Cefixime; D002439:Cefotaxime